TheraRadar
Landscape / Oncology
Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

NSCLC Clinical Trial Landscape

Non-small cell lung cancer (NSCLC) is a common type of lung cancer that affects cells in the airways. Clinical trials are essential for developing new and improved treatments for this disease.

Since 2008, 3,308 NSCLC trials have been registered, with 1,428 currently active, meaning they are recruiting, enrolling, or active but not recruiting patients. The majority of active trials are in Phase 1 and Phase 2, with 523 and 886 trials respectively, suggesting a strong focus on early-stage drug development.

Phase 3 trials account for 278 active trials, while Phase 4 has 19. AstraZeneca leads industry sponsorship with 57 active trials, followed by Merck (25 active), Roche (19 active), Eli Lilly (17 active), and Sichuan Baili Pharmaceutical Co., Ltd. (17 active).

The high volume of Phase 2 trials compared to Phase 3 suggests a large number of therapies are being evaluated for efficacy before moving to late-stage development.

Trial activity

1,467 active / 3,387 total since 2008
Active by phase 284 Ph3 / 551 878 Ph2 / 1907 284 Ph1 / 856 21 Ph4 / 73

Competitive Intelligence

This NSCLC competitive landscape maps 30 companies against 16 mechanisms of action (MOA) across 45 active drug-development programs, including 2 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in NSCLC, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

✨ Free preview of Pro. Filters, selection & export are unlocked on this page so you can try them. Unlock them everywhere →
Beta 30 companies of 41 16 mechanisms of 57 45 programs mapped 9 lowTrust (20%) 2 ⚖ PDUFA-dated ⏰ 9 due ≤6 mo click any cell → asset tearsheet
At a glance

Non-Small Cell Lung Cancer shows 45 programs across 30 companies and 16 mechanisms. The most contested mechanism is EGFR (next-gen TKI) (19 programs).

Key findings
  • 52% of EGFR programs (15 of 29) are combos with novel agents — class-extension work, not class-validation.
  • Top 3 mechanisms (EGFR, EGFR (next-gen TKI), KRAS G12C) account for ~17% of programs — class concentration is low.
  • AstraZeneca runs 33 programs — the deepest pipeline in this view.
  • 83 hot readouts in next 6 months — most imminent: AbbVie (c-MET ADC).
  • 108 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 87 single-program mechanisms in the long tail — 17 are Ph2+ first-in-class first-mover bets.
  • 73 NME candidates in the long tail.
  • Most-novel-of-novel: Chia Tai Tianqing Pharmaceutical Group c-MET-selective multikinase inhibitor (c-MET / VEGFR / RET / c-KIT) (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 9 due ≤6 mo⚖ 2 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet. · showing top 30 of 41 companies × top 16 of 57 mechanisms by program count — long tail omitted for width, not a data cap.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
KRAS G12C
EGFR (next-gen TKI)
EGFR
EGFR (osimertinib)
PD-1 / VEGF bispecific
TROP-2 ADC (next-gen)
HER2
HER2 ADC
PD-1 / TIGIT bispecific
EGFR / HER3 bispecific ADC
PD-L1 ADC
c-MET ADC
Trop-2 ADC
MTAP / PRMT5
PD-L1 / VEGF-A bispecific antibody
LAG-3
AstraZeneca
Merck & Co.
🇨🇳Sichuan Baili
Bristol-Myers Squibb
🇨🇳Shanghai Henlius
🇨🇳Akeso
Allist
🇨🇳Jiangsu Hansoh
Dizal
Novartis
AbbVie
Pfizer
Roche / Genentech
Amgen
Daiichi Sankyo
🇨🇳Jiangsu HengRui Medicine
Regeneron
Avistone
Boehringer Ingelheim
Eli Lilly
🇨🇳Hansoh BioMedical R&D Company
🇨🇳Sichuan Kelun-Biotech Biophar…
Betta
Nuvalent
🇨🇳Shanghai JMT-Bio
ArriVent BioPharma
BioNTech
CSPC Megalith Biopharmaceutic…
Summit
Taiho Oncology

Phase 3 leaders · most advanced

  1. active Daiichi Sankyo NCT05215340
  2. recruiting Bristol-Myers Squibb NCT07361510
  3. recruiting Mirati Therapeutics Inc. NCT06875310
  4. recruiting AbbVie NCT07005102
  5. recruiting Shanghai Chest Hospital NCT06437977

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 29 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (87) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph3 c-MET-selective multikinase inhibitor (c-MET / VEGFR / RET / c-… ⚡ 🌱 🆕 Chia Tai Tianqing Pharmac… Oral 3Q25 NCT05922345
Ph3 Chemo (Gem/nab-paclitaxel) 🌱 Merck & Co. SC 4Q24 NCT06212752
Ph3 CTLA-4 (pH-sensitive) 🌱 🆕 OncoC4 IV 3Q27 NCT05671510
Ph2+Ph3 GARP:TGF-β1 complex antibody 🌱 🆕 AbbVie IV 4Q31 NCT06236438
Ph3 IL-15 superagonist 🌱 🆕 ImmunityBio IV 3Q28 NCT06745908
Ph3 MHC-II agonist (soluble LAG-3) 🌱 🆕 Immutep S.A.S. IV 2Q27 NCT06726265
Ph3 Microtubule destabilizer ⚡ 🌱 🆕 ⚙️ BeyondSpring IV 2Q29 NCT07361484
Ph3 Pan-RAS / RAS(ON) multi 🌱 🆕 Revolution Medicines IV 4Q27 NCT06881784
Ph3 PARP 🌱 Merck & Co. IV 2Q27 NCT04380636
Ph3 PD-1 (sintilimab) 🌱 Innovent Biologics (Suzho… IV ⏰ 3Q26 NCT05116462
Ph3 PD-1 / CTLA-4 bispecific 🌱 🆕 Akeso ⏰ 4Q26 NCT06617416
Ph3 PD-L1 (atezolizumab) 🌱 Roche / Genentech IV 4Q25 NCT05047250
Ph3 PD-L1 (avelumab) 🌱 EMD Serono Research & Dev… IV ⏰ 3Q26 NCT03815643
Ph3 PD-L1 x 4-1BB bispecific antibody 🌱 🆕 Genmab IV 3Q27 NCT06635824
Ph3 PROGESTERONE RECEPTOR 🌱 Changchun GeneScience Oral 2Q27 NCT07150663
Ph3 ROS1 / ALK 🌱 Shenzhen TargetRx Oral ⏰ 2Q26 NCT06082635
Ph3 TPO receptor agonist 🌱 Amgen 1Q26 NCT03937154
Ph2 ADORA2A ⚡ 🌱 🆕 iTeos IV 2Q25 NCT05403385
Ph2 Anti-BTN1A1 (mAb) 🌱 ⚙️ STCube IV 3Q27 NCT07306624
Ph2 Anti-PD-1 🌱 🆕 ⚙️ CrystalGenomics IV ⏰ 3Q26 NCT05841472
Ph1+Ph2 Anti-PD-1 (mAb) 🌱 🆕 ⚙️ Henan Genuine 3Q27 NCT07362940
Ph2 Anti-PD-L1 (mAb) 🌱 🆕 ⚙️ Chia Tai Tianqing Pharmac… Oral ⏰ 2Q26 NCT05913089
Ph2 Autologous NK cell 🌱 🆕 ⚙️ Shenzhen Celconta Life Sc… 3Q28 NCT07043907
Ph1+Ph2 CHK1 inhibitor ⚡ 🌱 🆕 Sumitomo Pharma America 4Q28 NCT06526819
Ph1+Ph2 DNA crosslinker ⚡ 🌱 🆕 ⚙️ Inhatarget IV ⏰ 4Q26 NCT06896890
Ph1+Ph2 EGFR (TKI) 🌱 🆕 Pierre Fabre Medicament 4Q27 NCT06567015
Ph1+Ph2 EGFR / HER2 inhibitor 🌱 🆕 ⚙️ BlossomHill 1Q29 NCT06706076
Ph2 EGFR × MET bispecific ⚡ 🌱 🆕 ⚙️ Betta 2Q28 NCT06885840
Ph1+Ph2 EGFR TKI 🌱 🆕 ⚙️ Wayshine Biopharm 2Q27 NCT06631989
Ph2 EGFR/ALK 🌱 🆕 Sichuan Baili IV 4Q25 NCT05020457
Ph1+Ph2 EpCAM × CD3 bispecific ⚡ 🌱 🆕 ⚙️ Wuhan YZY Biopharma IV ⏰ 3Q26 NCT05543330
Ph1+Ph2 EZH1/2 🌱 🆕 Daiichi Sankyo IV 1Q28 NCT06644768
Ph2 EZH2 inhibitor ⚡ 🌱 ⚙️ Jiangsu HengRui Medicine 4Q28 NCT07175220
Ph2 Fluorescence imaging agent 🌱 🆕 ⚙️ Integro Theranostics ⏰ 3Q26 NCT07276789
Ph1+Ph2 FOLR1 🌱 Eisai Oral 3Q30 NCT04300556
Ph2 FRα ADC 🌱 🆕 Genmab 4Q27 NCT07288177
Ph2 HER2 × PD-L1 bispecific ⚡ 🌱 🆕 ⚙️ Jiangsu Alphamab Biopharm… IV 2Q27 NCT06775483
Ph1+Ph2 IL-15 agonist (cytoTIL) 🌱 🆕 ⚙️ Obsidian 2Q29 NCT06060613
Ph1+Ph2 LRRK2 inhibitor 🌱 🆕 ⚙️ Yuhan Corporation 1Q28 NCT06616766
Ph2 MEK inhibitor 🌱 🆕 ⚙️ Shanghai Fosun Pharmaceut… 2Q29 NCT07562581
Ph2 Microtubule stabilizer 🌱 🆕 ⚙️ ToLymph IV ⏰ 4Q26 NCT06693336
Ph2 MUC16 × CD3 🌱 🆕 Regeneron 2Q30 NCT07154290
Ph1+Ph2 NAPI2B 🌱 🆕 Tubulis 4Q27 NCT06303505
Ph1+Ph2 NTRK 🌱 🆕 Xuanzhu Biopharmaceutical 3Q25 NCT04996121
Ph2 PD-1 / CTLA-4 / VEGF trispecific antibody ⚡ 🌱 🆕 HC Biopharma ⏰ 4Q26 NCT07169552
Ph1+Ph2 PD-1 / TIM-3 bispecific 🌱 🆕 AstraZeneca 4Q24 NCT04931654
Ph2 PD-1 × IL-2 bispecific 🌱 🆕 ⚙️ Innovent Biologics (Suzho… ⏰ 4Q26 NCT07402070
Ph1+Ph2 PD-1 × TIGIT bispecific ⚡ 🌱 🆕 ⚙️ Suzhou Zelgen Biopharmace… 2Q27 NCT06903377
Ph1+Ph2 PD-1 gene-edited TIL therapy 🌱 🆕 ⚙️ Iovance Biotherapeutics 3Q27 NCT05361174
Ph2 PD-1 inhibitor 🌱 🆕 Shenyang Sunshine IV ⏰ 3Q26 NCT07171606
Ph2 PD-L1 × IL-15 bispecific ⚡ 🌱 🆕 ⚙️ Jiangsu Alphamab Biopharm… 3Q27 NCT07283198
Ph2 PDCD1/PD-L1 ⚡ 🌱 🆕 CellSight Technologies Radioligand 4Q25 NCT06107374
Ph1+Ph2 PRMT5 inhibitor (MTA-cooperative) ⚡ 🌱 🆕 Bayer 2Q29 NCT06914128
Ph1+Ph2 SOS1 inhibitor ⚡ 🌱 🆕 ⚙️ Jiangsu Hansoh 1Q25 NCT05435248
Ph1+Ph2 STK11 ⚡ 🌱 🆕 Tango IV 1Q26 NCT05887492
Ph1+Ph2 T CELL RECEPTOR 🌱 🆕 Marengo ⏰ 4Q26 NCT05592626
Ph2 T-cell PET tracer ⚡ 🌱 🆕 ⚙️ CellSight Technologies 4Q25 NCT06084806
Ph2 TIL therapy 🌱 🆕 Iovance Biotherapeutics 4Q30 NCT04614103
Ph2 TIL therapy (BlueHorse) 🌱 🆕 Suzhou BlueHorse 4Q27 NCT07444437
Ph1+Ph2 TROP2 ADC 🌱 🆕 Sichuan Baili 4Q25 NCT05949619
Ph1 A2A antagonist ⚡ 🌱 🆕 ⚙️ Arcus IV ⏰ 4Q26 NCT06120075
Ph1 Allogeneic γδ T cell therapy ⚡ 🌱 🆕 ⚙️ Kiromic BioPharma 4Q25 NCT06069570
Ph1 BCL-2 inhibitor 🌱 Ascentage Pharma Group Oral 4Q25 NCT04001777
Ph1 BRAF 🌱 🆕 Pierre Fabre Medicament Oral 4Q28 NCT04913285
Ph1 CBP/p300 inhibitor 🌱 🆕 Aurigene Discovery Techno… ⏰ 1Q27 NCT05865002
Ph1 CD3 tetraspecific T-cell engager 🌱 🆕 Sichuan Baili ⏰ 4Q26 NCT06612840
Ph1 Claudin 6 🌱 🆕 BioNTech Cell & Gene Ther… Cell therapy 3Q28 NCT04503278
Ph1 EGFR × c-MET (ADC) 🌱 🆕 Doma Biopharmaceutical（Su… ⏰ 4Q26 NCT06515990
Ph1 EGFR degrader (PROTAC) 🌱 🆕 ⚙️ Betta Oral 4Q25 NCT06641609
Ph1 EGFR TKI (3rd gen) ⚡ 🌱 🆕 ⚙️ Allist ⏰ 4Q26 NCT06955988
Ph1 GDF-15 (cachexia) 🌱 🆕 Pfizer 1Q28 NCT07663630
Ph1 GPC3 🌱 🆕 Aptamer Sciences 4Q27 NCT06687941
Ph1 KAT6 inhibitor 🌱 🆕 Olema 2Q27 NCT06784193
Ph1 KRAS G12D degrader 🌱 🆕 Astellas Pharma 2Q27 NCT06364696
Ph1 KRASG12C 🌱 🆕 TheRas, Inc., d/b/a BBOT … IV 2Q31 NCT06343402
Ph1 Multikinase (VEGFR) 🌱 AbbVie IV 3Q30 NCT06858813
Ph1 Oncolytic adenovirus (TNFα/IL-2 armed) 🌱 🆕 TILT Biotherapeutics IV 1Q26 NCT06125197
Ph1 Pan-KRAS inhibitor 🌱 🆕 Pfizer 1Q28 NCT06447662
Ph1 PD-1 (nivolumab) 🌱 🆕 Ono IV ⏰ 3Q26 NCT06542731
Ph1 PD-1 (tislelizumab) 🌱 🆕 BeiGene SC 3Q25 NCT06091943
Ph1 PD-L1 × VEGF bispecific 🌱 🆕 RemeGen IV ⏰ 3Q26 NCT06883630
Ph1 PTK7 ADC 🌱 🆕 Whitehawk 4Q28 NCT07444814
Ph1 ROS1 / ALK / MET inhibitor ⚡ 🌱 🆕 ⚙️ Shenzhen TargetRx 3Q25 NCT05441956
Ph1 TIM-3 inhibitor 🌱 🆕 GSK IV 1Q27 NCT02817633
Ph1 TROP2 in vivo mRNA CAR 🌱 🆕 Myeloid 3Q27 NCT05969041
Ph1 Tyrosine-protein kinase receptor FLT3 inhibitor 🌱 Astellas Pharma Global De… 4Q29 NCT07140016
Ph1 WEE1 molecular glue degrader 🌱 🆕 Bristol-Myers Squibb 4Q28 NCT06476808
Emerging & small-cap sponsors (83) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph2 KRAS G12C Abbisko Oral 4Q28 NCT07164170
Ph1 KRAS G12C inhibitor ⚡ Abbisko 1Q27 NCT06225804
Ph2 TIGIT Arcus IV 2Q27 NCT04736173
Ph2 EGFR BeBetter Med Oral 4Q25 NCT06706713
Ph2 EGFR BeBetter Med IV 2Q27 NCT06514027
Ph2 🇨🇳 OX40 BeiGene IV 4Q25 NCT05635708
Ph3 🇨🇳 MET Beijing Pearl Biotechnolo… ⏰ 3Q26 NCT05989542
Ph3 🇨🇳 c-MET TKI Beijing Pearl Biotechnolo… 1Q29 NCT06930794
Ph2 GMCI / gene therapy Candel 4Q24 NCT04495153
Ph3 GMCI / gene therapy Candel IV 4Q31 NCT07660094
Ph2 Anti-GDF-15 CatalYm IV 1Q29 NCT07098988
Ph2 Anti-GDF-15 CatalYm IV 4Q29 NCT07246863
Ph1 🇨🇳 EGFR (next-gen TKI) Chia Tai Tianqing Pharmac… 4Q25 NCT06585059
Ph2 🇨🇳 DLL3 ADC Chia Tai Tianqing Pharmac… ⏰ 2Q26 NCT06496490
Ph2+Ph3 TLR7/8 agonist Eikon IV 4Q35 NCT07365319
Ph2 TLR7/8 agonist Eikon IV ⏰ 4Q26 NCT06246110
Ph2 🇨🇳 KRAS G12D Genfleet Therapeutics (Sh… 2Q27 NCT07554859
Ph3 🇨🇳 KRAS G12D Genfleet Therapeutics (Sh… IV 2Q30 NCT07668752
Ph2 Trop-2 ADC Gilead Sciences IV ⏰ 3Q26 NCT05186974
Ph3 TIGIT Gilead Sciences IV 2Q28 NCT05502237
Ph1+Ph2 EGFR inhibitor Henan Genuine 4Q27 NCT07231068
Ph3 🇨🇳 FAK inhibitor InxMed (Shanghai) IV 3Q28 NCT07174908
Ph1+Ph2 🇨🇳 FAK inhibitor InxMed (Shanghai) ⏰ 3Q26 NCT05994131
Ph3 🇨🇳 KRAS Jemincare IV 4Q27 NCT07242274
Ph1 🇨🇳 KRAS Jemincare IV 1Q26 NCT06946927
Ph2 Telomere-targeting agent (telomerase substrate) Maia Biotechnology IV 3Q27 NCT05208944
Ph3 Telomere-targeting agent (telomerase substrate) Maia Biotechnology IV 3Q27 NCT06908304
Ph3 🇨🇳 HER3 ADC MediLink Therapeutics (Su… IV 3Q28 NCT07416994
Ph1 🇨🇳 HER3 ADC MediLink Therapeutics (Su… ⏰ 4Q26 NCT05653752
Ph3 Cancer vaccine (peptide) ⚡ OSE Immunotherapeutics IV 4Q27 NCT06472245
Ph1+Ph2 Cancer vaccine (peptide) ⚡ OSE Immunotherapeutics 4Q29 NCT05751798
Ph3 🇨🇳 PD-1 × CTLA-4 bispecific Qilu 2Q29 NCT05690945
Ph3 🇨🇳 PD-1 × CTLA-4 bispecific Qilu IV 3Q27 NCT05487391
Ph2 🇨🇳 EGFR (next-gen TKI) RemeGen ⏰ 2Q26 NCT06962865
Ph1 PD-1 inhibitor (pembrolizumab biosimilar) Samsung Bioepis IV 1Q26 NCT06268613
Ph3 PD-1 inhibitor (pembrolizumab biosimilar) Samsung Bioepis IV 1Q26 NCT06348199
Ph1 🇨🇳 SHP2 inhibitor Shanghai Fosun Pharmaceut… 2Q30 NCT07558200
Ph3 🇨🇳 PD-L1 / VEGF bispecific Shanghai Huaota Biopharma… IV 2Q28 NCT07383116
Ph3 🇨🇳 PD-L1 / VEGF bispecific Shanghai Huaota Biopharma… IV 2Q28 NCT07360132
Ph3 PD-1 × VEGF bispecific Shenyang Sunshine IV ⏰ 3Q26 NCT06980272
Ph3 🇨🇳 EGFR Suzhou Puhe Pharmaceutica… Oral 3Q25 NCT05767892
Ph1+Ph2 🇨🇳 EGFR inhibitor Suzhou Puhe Pharmaceutica… Oral ⏰ 2Q26 NCT06590194
Ph3 EGFR exon 20 Takeda IV ⏰ 4Q26 NCT04129502
Ph1+Ph2 EGFR exon 20 Takeda ⏰ 4Q26 NCT02716116
Ph1+Ph2 MTAP / PRMT5 Tango IV 2Q27 NCT06922591
Ph2 VEGFR Teligene US Oral 4Q27 NCT05168566
Ph2 VEGFR Teligene US Oral 4Q27 NCT06010329
Ph2 CD73 antibody TJ Biopharma IV ⏰ 3Q26 NCT07005336
Ph2+Ph3 CD73 antibody TJ Biopharma IV 3Q28 NCT06984588
Ph1+Ph2 EGFR (osimertinib) Wayshine Biopharm Oral 4Q28 NCT07206498
Ph1 Multi-kinase inhibitor (Advenchen) Advenchen Laboratories 4Q27 NCT06794957
Ph2 Multi-kinase inhibitor (Advenchen) Advenchen Pharmaceuticals… 4Q27 NCT05363280
Ph1 🇨🇳 EGFR (osimertinib) Alpha Biopharma (Jiangsu) Oral 2Q28 NCT07361705
Ph1 IL-2 Ankyra 2Q27 NCT07027514
Ph1+Ph2 EGFR inhibitor Avistone Pharmaceutical（N… Oral 1Q28 NCT07063329
Ph2 Nectin-4 ADC BicycleTx Limited 3Q28 NCT06933329
Ph2 PD-L1 / VEGF-A bispecific antibody Biotheus IV 3Q24 NCT05756972
Ph1+Ph2 EGFR (next-gen TKI) Black Diamond 4Q25 NCT05256290
Ph1+Ph2 EGFR Bridge Biotherapeutics ⏰ 3Q26 NCT05920135
Ph1 EGFR ADC Conjupro Biotherapeutics 2Q27 NCT05948865
Ph2 MET CSPC ZhongQi Pharmaceutic… IV ⏰ 4Q26 NCT06525350
Ph1+Ph2 EGFR (next-gen TKI) Cullinan 4Q25 NCT04036682
Ph3 🇨🇳 EGFR exon 20 Dizal (Jiangsu) 3Q29 NCT07182682
Ph2 PD-L1 / VEGF-A bispecific antibody DualityBio 2Q30 NCT06953089
Ph2 OX40 Elpiscience IV 1Q27 NCT06623136
Ph1 HER2 Enliven IV ⏰ 3Q26 NCT05650879
Ph1 EGFR EpiBiologics 3Q29 NCT07462377
Ph1 🇨🇳 PD-1 / VEGF bispecific Everest Medicines (Beijin… 3Q28 NCT07614646
Ph1 KRAS GeneCraft ⏰ 3Q26 NCT06934590
Ph1+Ph2 EGFR (osimertinib) Genprex Oral 1Q28 NCT04486833
Ph3 🇨🇳 ROS1 Guangzhou JOYO Pharma IV 4Q27 NCT07154368
Ph1 EGFR Haisco Pharmaceutical Gro… 3Q25 NCT06050980
Ph3 c-MET TKI Hutchison Medipharma Limi… Oral 2Q28 NCT05009836
Ph1 KRAS G12D Incyte Corporation IV ⏰ 1Q27 NCT06179160
Ph2 PD-L1 (durvalumab) Innate Pharma IV 2Q27 NCT05742607
Ph1+Ph2 EGFR J Ints Bio ⏰ 3Q26 NCT05394831
Ph3 🇨🇳 EGFR (next-gen TKI) Jiangsu Aosaikang IV 4Q27 NCT07109531
Ph3 🇨🇳 EGFR Jiangsu Chia Tai Fenghai Oral 1Q25 NCT06759857
Ph2 🇨🇳 TROP-2 ADC (next-gen) Klus Pharma IV ⏰ 2Q26 NCT05816252
Ph3 PD-1 (pembrolizumab) Laboratorio Elea Phoenix IV 3Q24 NCT05668650
Ph2 Undisclosed target Lantern Pharma IV ⏰ 4Q26 NCT05456256
Ph3 Anti-VEGF (bevacizumab) Mabscale IV ⏰ 4Q26 NCT05654454
Ph3 PD-1 (pembrolizumab) mAbxience Research S.L. IV ⏰ 2Q26 NCT06687369
Ph3 🇨🇳 EGFR Nanjing Sanhome 1Q28 NCT06080776
Ph1 EGFR Newsoara Biopharma ⏰ 4Q26 NCT06218940
Ph3 PD-1 (pembrolizumab) NovoCure IV 4Q28 NCT06216301
Ph2 EGFR OBI Pharma Oral 4Q25 NCT05442060
Ph1 EGFR / MET bispecific ORIC SC ⏰ 4Q26 NCT06816992
Ph1+Ph2 KRAS G12C Orion Corporation, Orion … IV 3Q29 NCT07563738
Ph2 HER2 Partner ⏰ 4Q26 NCT02912949
Ph1+Ph2 CD73 Phanes IV 4Q27 NCT05431270
Ph1 🇨🇳 IL-2 Qingdao Sino-Cell Biomedi… IV ⏰ 3Q26 NCT07105176
Ph1+Ph2 MTAP / PRMT5 Servier Bio-Innovation Oral 2Q27 NCT06188702
Ph1+Ph2 🇨🇳 CTLA-4 (Hengrui) Shanghai Hengrui ⏰ 2Q26 NCT06589778
Ph2+Ph3 🇨🇳 PD-L1 (adebrelimab) Shanghai Shengdi IV 4Q28 NCT06335355
Ph1+Ph2 🇨🇳 SHP2 inhibitor Sichuan Huiyu 2Q28 NCT06712680
Ph1 🇨🇳 CD47 / SIRPα Sichuan Luzhou Buchang Bi… ⏰ 2Q26 NCT06773507
Ph3 🇨🇳 PD-1 / VEGF bispecific Sinocelltech IV 3Q27 NCT07362459
Ph1+Ph2 🇨🇳 CD47 / SIRPα SUNHO（China）BioPharmaceut… 3Q29 NCT06581419
Ph2 🇨🇳 PD-1 × VEGF bispecific Sunshine Guojian Pharmace… IV 3Q25 NCT06412471
Ph1+Ph2 🇨🇳 EGFR Suzhou Junjing 4Q25 NCT06940401
Ph1+Ph2 ALK TRIANA Biomedicines 2Q29 NCT07491497
Ph1+Ph2 KRAS G12C inhibitor ⚡ Xcovery Holdings 1Q28 NCT05393466
Ph1 Undisclosed target Zymeworks BC 3Q27 NCT07164313
Unclassified programs (116) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph3 SYS6010, Osimertinib, platinum-pemetrexedunclassified CSPC Megalith Biopharmace… NCT07376382
Ph3 SKB264, Osimertinibunclassified Sichuan Kelun-Biotech Bio… NCT06670196
Ph3 Alectinib, Entrectinib, Durvalumabunclassified Hoffmann-La Roche NCT05170204
Ph3 Osimertinib, Datopotamab Deruxtecanunclassified AstraZeneca NCT06350097
Ph3 TAK-928, Control Armunclassified Takeda NCT07217301
Ph3 Durvalumab, (Osimertinib cohort, single-arm, open-label separat…unclassified AstraZeneca NCT03833154
Ph3 RC148 plus Carboplatin and Paclitaxel, Tislelizumab plus Carbop…unclassified RemeGen Co., Ltd. NCT07416474
Ph3 BL-B01D1, Osimertinib, Osimertinibunclassified Sichuan Baili Pharmaceuti… NCT06838273
Ph3 Pembrolizumab, Atezolizumab, Cemiplimabunclassified InSightec NCT05317858
Ph3 SHR-A2009 ; Aumolertinib, Aumolertinibunclassified Suzhou Suncadia Biopharma… NCT07183189
Ph3 Savolitinib, Osimertinib, Pemetrexedunclassified AstraZeneca NCT05261399
Ph3 Envalfolimab subcutaneously injected+Platinum-based doublet che…unclassified 3D Medicines (Sichuan) Co… NCT06123754
Ph2+Ph3 Alectinib, Atezolizumab, Pemetrexedunclassified Hoffmann-La Roche NCT03178552
Ph3 Dato-DXd, Osimertinib, Pemetrexedunclassified AstraZeneca NCT06417814
Ph3 Entrectinib, Crizotinibunclassified Hoffmann-La Roche NCT04603807
Ph3 Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplati…unclassified Allist Pharmaceuticals, I… NCT06970639
Ph2+Ph3 HLX07, HLX07 placebo, Serplulimabunclassified Shanghai Henlius Biotech NCT07318883
Ph3 Repotrectinib, Crizotinibunclassified Bristol-Myers Squibb NCT06140836
Ph3 X-396 (ensartinib), crizotinibunclassified Xcovery Holdings, Inc. NCT02767804
Ph3 Cobolimab, Dostarlimab, Docetaxelunclassified GlaxoSmithKline NCT04655976
Ph3 QL2107, Keytruda®unclassified Qilu Pharmaceutical Co., … NCT07162883
Ph3 Vebreltinib, PLB1004, Pemetrexed plus Carboplatin or Cisplatinunclassified Avistone Biotechnology Co… NCT06970782
Ph3 JAB-21822, Tislelizumab, JAB-3312unclassified Allist Pharmaceuticals, I… NCT06416410
Ph2+Ph3 Glumetinib Tablets, Osimertinib Mesylate Tablets, Glumetinib Ta…unclassified Shanghai JMT-Bio Inc. NCT06908772
Ph3 Study Of Comparing SAF-189s With Crizotinib In First Line ALK-P…unclassified Shanghai Fosun Pharmaceut… NCT06569420
Ph3 Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebounclassified Betta Pharmaceuticals Co.… NCT06041776
Ph3 AK104, Tislelizumab, carboplatinunclassified Akeso NCT05990127
Ph3 HRS-7058, Fulzerasib Tablets, Garsorasib Tabletsunclassified Shandong Suncadia Medicin… NCT07601048
Ph2+Ph3 BL-B01D1, Osimertinib, Carboplatinunclassified Sichuan Baili Pharmaceuti… NCT07642024
Ph3 BL-B01D1, Osimertinibunclassified Sichuan Baili Pharmaceuti… NCT07640789
Ph3 SYS6010 injection, Enlonstobart injection, Tislelizumab injecti…unclassified CSPC Megalith Biopharmace… NCT07633873
Ph2+Ph3 SCTB41, Tislelizumab, Paclitaxelunclassified Sinocelltech Ltd. NCT07662395
Ph2 MK-1084, Pembrolizumab, Cetuximabunclassified Merck Sharp & Dohme LLC NCT07252739
Ph2 Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxelunclassified Merck Sharp & Dohme LLC NCT06780085
Ph2 JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (c…unclassified Johnson & Johnson Enterpr… NCT06667908
Ph2 Sacituzumab Tirumotecan, Osimertinibunclassified Sichuan Kelun-Biotech Bio… NCT07329322
Ph1+Ph2 DZD6008, Sunvozertinib, Osimertinibunclassified Dizal (Jiangsu) Pharmaceu… NCT07079475
Ph1+Ph2 S095018, S095024, S095029unclassified Servier Bio-Innovation LLC NCT06162572
Ph2 Amivantamab IV, Amivantamab SC, Lazertinibunclassified Janssen Research & Develo… NCT06120140
Ph2 Amivantamab, Lazertinib, Chemotherapy: Pemetrexedunclassified Janssen Research & Develo… NCT06667076
Ph1+Ph2 Amivantamab, Olomorasibunclassified Janssen Research & Develo… NCT07227025
Ph1+Ph2 Capmatinib, Amivantamabunclassified Janssen Research & Develo… NCT05488314
Ph2 BNT116, Cemiplimabunclassified Regeneron Pharmaceuticals NCT05557591
Ph1+Ph2 BNT326, BNT327, Pembrolizumabunclassified BioNTech SE NCT07111520
Ph2 Autologous Tumor Infiltrating Lymphocytesunclassified Shanghai Juncell Therapeu… NCT07560111
Ph2 Rilvegostomig, Ramucirumab, Dato-DXdunclassified AstraZeneca NCT07098338
Ph1+Ph2 Elironrasib, Daraxonrasibunclassified Revolution Medicines, Inc. NCT06128551
Ph2 osimertinib, savolitinib, placebounclassified AstraZeneca NCT03778229
Ph2 TATE and pembrolizumab, TAS-102 pill, Regorafenib Pillunclassified Teclison Ltd. NCT04701476
Ph2 PF-07248144, Fulvestrant, Letrozoleunclassified Pfizer NCT04606446
Ph1+Ph2 BMS-986523, Gemcitabine, Nab-Paclitaxelunclassified Bristol-Myers Squibb NCT07223047
Ph1+Ph2 MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecanunclassified Merck Sharp & Dohme LLC NCT07286149
Ph2 Alectinib, Entrectinib, Vemurafenibunclassified Genentech, Inc. NCT04302025
Ph2 Study to Investigate Petosemtamab in Adults With Metastatic Non…unclassified Merus B.V. NCT07353957
Ph2 Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabineunclassified Merck Sharp & Dohme LLC NCT06788912
Ph2 Osimertinib, Amivantamabunclassified AstraZeneca NCT05801029
Ph2 Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-h…unclassified Gilead Sciences NCT05633667
Ph1+Ph2 SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + p…unclassified Shanghai JMT-Bio Inc. NCT07472647
Ph1+Ph2 Pembrolizumab, Carboplatin, Paclitaxelunclassified Merck Sharp & Dohme LLC NCT04165070
Ph1+Ph2 Dual-target CAR-NK cells, Lymphodepleting chemotherapyunclassified Beijing Biotech NCT07467863
Ph2 ILKN421H, Pembrolizumabunclassified iLeukon Therapeutics, Inc. NCT07452224
Ph2 Durvalumab, Oleclumab, Monalizumabunclassified AstraZeneca NCT05061550
Ph1+Ph2 RMC-6291, RMC-6236, Pembrolizumabunclassified Revolution Medicines, Inc. NCT06162221
Ph1+Ph2 M1774, Cemiplimabunclassified EMD Serono Research & Dev… NCT05882734
Ph2 RP1, nivolumabunclassified Replimune, Inc. NCT03767348
Ph2 Cemiplimab, Platinum-based chemotherapy, REGN7075unclassified Regeneron Pharmaceuticals NCT06465329
Ph1+Ph2 Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xen…unclassified Xemed LLC NCT07355231
Ph1+Ph2 SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injec…unclassified Shanghai Hengrui Pharmace… NCT06512051
Ph1+Ph2 LNS8801 -Small molecule, orally bioavailable, selective agonist…unclassified Linnaeus Therapeutics, In… NCT04130516
Ph1+Ph2 ANS014004 + PLB1004, ANS014004 + Osimertinibunclassified Beijing Pearl Biotechnolo… NCT07285148
Ph2 SYS6010, Osimertinib, Pemetrexedunclassified CSPC Megalith Biopharmace… NCT07256509
Ph2 SHR-A2102, Adebrelimab, Paclitaxelunclassified Shanghai Hengrui Pharmace… NCT07229729
Ph1+Ph2 Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and…unclassified Stella Pharma Corporation NCT06603987
Ph2 Durvalumab, Danvatirsen, Ceralasertibunclassified AstraZeneca NCT03334617
Ph1+Ph2 KB707, Pembrolizumab (KEYTRUDA®), Chemotherapyunclassified Krystal Biotech, Inc. NCT06228326
Ph2 Pemetrexed, Cisplatin, IBI363unclassified Innovent Biologics (Suzho… NCT07122687
Ph2 Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin…unclassified Genelux Corporation NCT06463665
Ph2 BL-B01D1, Osimertinib Mesylate Tabletsunclassified Sichuan Baili Pharmaceuti… NCT05880706
Ph2 WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose leve…unclassified Wayshine Biopharm, Inc. NCT06868485
Ph2 Pembrolizumab, FF-10832unclassified Fujifilm Pharmaceuticals … NCT05318573
Ph1+Ph2 PDC*lung01, Keytruda Injectable Product, Alimta Injectable Prod…unclassified PDC*line Pharma SAS NCT03970746
Ph2 Vebreltinib, Osimertinib, PLB1004unclassified Avistone Biotechnology Co… NCT06574347
Ph1+Ph2 Vebreltinib, PLB1004unclassified Avistone Biotechnology Co… NCT06343064
Ph2 BL-B01D1, Osimertinib Mesylate Tabletsunclassified Sichuan Baili Pharmaceuti… NCT06498986
Ph1+Ph2 JAB-21822, JAB-3312unclassified Allist Pharmaceuticals, I… NCT05288205
Ph1+Ph2 donor-derived NK cell infusionunclassified Precision Biotech Taiwan … NCT04616209
Ph2 Utidelone combined with Bevacizumab, Utidelone, Utidelone combi…unclassified Beijing Biostar Pharmaceu… NCT06683703
Ph1+Ph2 RC108unclassified RemeGen Co., Ltd. NCT05821933
Ph2 A Study of Oncobax®-AK in Patients With Advanced Solid Tumorsunclassified EverImmune NCT05865730
Ph1+Ph2 Almonertinib combined with SHR-1701, Almonertinibunclassified Suzhou Suncadia Biopharma… NCT05503888
Ph2 Amivantamab, Lazertinib, Carboplatinunclassified Janssen Research & Develo… NCT07586202
Ph2 SCTB41, docetaxelunclassified Sinocelltech Ltd. NCT07609251
Ph2 ALK202 for injectionunclassified Shanghai Allink Biotherap… NCT07603791
Ph2 SKB571 for injection, Osimertinib, Furmonertinibunclassified Sichuan Kelun-Biotech Bio… NCT07622186
Ph1+Ph2 Dual-target CAR-NK cells, Lymphodepleting chemotherapyunclassified Beijing Biotech NCT07641023
Ph1 JNJ-86974680, Cetrelimabunclassified Johnson & Johnson Enterpr… NCT06116786
Ph1 Lazertinib, Amivantamab, Carboplatinunclassified Janssen Research & Develo… NCT04077463
Ph1 BNT116, Cemiplimab, Docetaxelunclassified BioNTech SE NCT05142189
Ph1 Datopotamab deruxtecan, Durvalumab, Carboplatinunclassified AstraZeneca NCT04612751
Ph1 JSKN016, Carboplatin, Furmonertinib Mesylateunclassified Jiangsu Alphamab Biopharm… NCT06868732
Ph1 KRAS-specific Autologous TCR-T cell injectionunclassified Corregene Biotechnology C… NCT06767046
Ph1 PRTH-101, Pembrolizumabunclassified Incendia Therapeutics NCT05753722
Ph1 AMG 410, Pembrolizumab, Panitumumabunclassified Amgen NCT07094113
Ph1 BAT3306, US-Keytruda®unclassified Bio-Thera Solutions NCT07180862
Ph1 NXP900, Osimertinibunclassified Nuvectis Pharma, Inc. NCT07315113
Ph1 Autologous Tumor Infiltrating Lymphocytesunclassified Shanghai Juncell Therapeu… NCT06473961
Ph1 Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwashunclassified Daiichi Sankyo Co., Ltd. NCT03401385
Ph1 ERAS-0015, ERAS-0015 in combinationunclassified Erasca, Inc. NCT06983743
Ph1 BT02unclassified Biotroy Therapeutics NCT07110363
Ph1 SDT-M001 injectionunclassified Cytocraft Biopharmaceutic… NCT07096882
Ph1 HER3-DXd, HER3-DXd, Osimertinibunclassified Daiichi Sankyo NCT04676477
Ph1 DM001unclassified Xadcera Biopharmaceutical… NCT06475937
Ph1 IBI351, Cetuximab, pemetrexedunclassified Innovent Biologics (Suzho… NCT05504278
Ph1 [14C] AZD6738, AZD6738 / ceralasertibunclassified AstraZeneca NCT06754761
Ph1 SNH-118110 Soft Capsulesunclassified ScinnoHub Pharmaceutical … NCT07649200
Ph1 HDM2020 (FGFR2b-ADC)unclassified Hangzhou Zhongmei Huadong… NCT07638891
Drugs in this landscape: Trastuzumab Deruxtecan · Sacituzumab Govitecan · Adagrasib · Sotorasib · Datopotamab Deruxtecan · zongertinib · Osimertinib mesylate

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
AstraZeneca 57 36 9
Merck 26 34 6
Sichuan Baili Pharmaceutical Co., Ltd. 19 0 0
Roche 17 80 12
Eli Lilly 17 47 9
Novartis 15 20 27
Pfizer 14 27 22
Johnson & Johnson 13 4 1
Bristol-Myers Squibb 12 36 11
Daiichi Sankyo 12 6 5
Allist Pharmaceuticals, Inc. 12 2 3
AbbVie 11 5 7
Akeso 11 3 1
Jiangsu Hansoh Pharmaceutical Co., Ltd. 11 0 0
Betta Pharmaceuticals Co., Ltd. 10 10 1

All 15 active NSCLC sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2025 (331 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (380 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
142
2017
174
2018
188
2019
177
2020
175
2021
231
2022
234
2023
242
2024
314
2025
331
2026
225

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (21)
291
2017 (20)
526
2018 (27)
360
2019 (25)
448
2020 (30)
356
2021 (34)
248
2022 (31)
324
2023 (35)
420
2024 (59)
432
2025 (60)
385
2026 (38)
450

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT07376382 NOT YET RECRUITING
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. n=680
NCT05215340 ACTIVE NOT RECRUITING
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo n=740
NCT07361510 RECRUITING
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb n=750
NCT06875310 RECRUITING
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc. n=630
NCT07005102 RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie n=854
NCT06437977 RECRUITING
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
Shanghai Chest Hospital n=478
NCT04928846 RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie n=698
NCT03706690 ACTIVE NOT RECRUITING
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
AstraZeneca n=407
NCT07513376 RECRUITING
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Merck Sharp & Dohme LLC n=876
NCT06686771 RECRUITING
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Canadian Cancer Trials Group n=320
NCT06119581 RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company n=1,264
NCT06074588 ACTIVE NOT RECRUITING
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Merck Sharp & Dohme LLC n=556
NCT06890598 RECRUITING
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company n=700
NCT06345729 RECRUITING
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Merck Sharp & Dohme LLC n=600
NCT07431827 RECRUITING
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Merck Sharp & Dohme LLC n=400
NCT06793215 RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche n=600
NCT07190248 RECRUITING
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Merck Sharp & Dohme LLC n=675
NCT04487080 ACTIVE NOT RECRUITING
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC n=1,074
NCT04538664 ACTIVE NOT RECRUITING
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Janssen Research & Development, LLC n=308
NCT06448312 ACTIVE NOT RECRUITING
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=406
NCT06670196 RECRUITING
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=420
NCT05388669 ACTIVE NOT RECRUITING
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC n=418
NCT06422143 RECRUITING
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Merck Sharp & Dohme LLC n=851
NCT05870319 ACTIVE NOT RECRUITING
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=376
NCT06170788 RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Merck Sharp & Dohme LLC n=614
NCT04988295 ACTIVE NOT RECRUITING
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Janssen Research & Development, LLC n=776
NCT06312137 RECRUITING
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC n=780
NCT05089734 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Gilead Sciences n=603
NCT06311721 ACTIVE NOT RECRUITING
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Amgen n=315
NCT07195695 RECRUITING
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Boehringer Ingelheim n=400
NCT05170204 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=68
NCT07063745 RECRUITING
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Bristol-Myers Squibb n=590
NCT06350097 RECRUITING
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca n=582
NCT04564157 ACTIVE NOT RECRUITING
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
Fundación GECP n=210
NCT06305754 ACTIVE NOT RECRUITING
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Merck Sharp & Dohme LLC n=520
NCT03521154 ACTIVE NOT RECRUITING
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
AstraZeneca n=216
NCT06765109 RECRUITING
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Nuvalent Inc. n=450
NCT06745908 RECRUITING
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
ImmunityBio, Inc. n=507
NCT07128199 ACTIVE NOT RECRUITING
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Taiho Oncology, Inc. n=360
NCT06635824 ACTIVE NOT RECRUITING
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Genmab n=191
NCT03456076 ACTIVE NOT RECRUITING
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche n=257
NCT06623422 RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Merck Sharp & Dohme LLC n=680
NCT06077760 RECRUITING
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Merck Sharp & Dohme LLC n=868
NCT04585490 RECRUITING
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Maximilian Diehn n=48
NCT07566052 RECRUITING
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Astellas Pharma Global Development, Inc. n=356
NCT06930794 RECRUITING
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Beijing Pearl Biotechnology Limited Liability Company n=300
NCT05920356 RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen n=750
NCT07361497 RECRUITING
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Bristol-Myers Squibb n=850
NCT02542293 ACTIVE NOT RECRUITING
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
AstraZeneca n=953
NCT07560358 NOT YET RECRUITING
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=204
NCT06692738 RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
AstraZeneca n=880
NCT06561386 RECRUITING
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Bristol-Myers Squibb n=1,000
NCT05987956 ACTIVE NOT RECRUITING
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600
NCT05899608 RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics n=1,600
NCT04303780 ACTIVE NOT RECRUITING
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
Amgen n=345
NCT06431633 RECRUITING
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Fundación GECP n=129
NCT02486718 ACTIVE NOT RECRUITING
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche n=1,280
NCT05671510 RECRUITING
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
OncoC4, Inc. n=630
NCT07291037 RECRUITING
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
AstraZeneca n=400
NCT07554846 NOT YET RECRUITING
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Fudan University n=759
NCT07554339 RECRUITING
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Merck Sharp & Dohme LLC n=310
NCT05522660 RECRUITING
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation n=180
NCT03833154 ACTIVE NOT RECRUITING
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
AstraZeneca n=724
NCT05120349 ACTIVE NOT RECRUITING
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
AstraZeneca n=390
NCT05211895 RECRUITING
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
AstraZeneca n=860
NCT05687266 ACTIVE NOT RECRUITING
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
AstraZeneca n=1,350
NCT07541170 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=400
NCT07144280 RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Pfizer n=680
NCT05132075 ACTIVE NOT RECRUITING
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals n=95
NCT04765059 ACTIVE NOT RECRUITING
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
AstraZeneca n=98
NCT06758401 RECRUITING
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Pfizer n=714
NCT07416474 RECRUITING
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd. n=574
NCT06838273 RECRUITING
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Sichuan Baili Pharmaceutical Co., Ltd. n=720
NCT07222566 RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer n=1,410
NCT06497556 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche n=338
NCT06382116 ACTIVE NOT RECRUITING
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
Sichuan Baili Pharmaceutical Co., Ltd. n=432
NCT06452277 RECRUITING
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer n=444
NCT06382129 ACTIVE NOT RECRUITING
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
Sichuan Baili Pharmaceutical Co., Ltd. n=698
NCT05317858 RECRUITING
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
InSightec n=30
NCT07100080 RECRUITING
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb n=500
NCT05450692 ACTIVE NOT RECRUITING
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
AstraZeneca n=594
NCT02468024 RECRUITING
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
University of Texas Southwestern Medical Center n=272
NCT06712316 RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE n=1,260
NCT06931717 RECRUITING
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
ETOP IBCSG Partners Foundation n=390
NCT05059522 ACTIVE NOT RECRUITING
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer n=77
NCT07154706 RECRUITING
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc. n=180
NCT06141070 RECRUITING
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
Vastra Gotaland Region n=240
NCT07183189 RECRUITING
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=576
NCT06564324 RECRUITING
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc. n=194
NCT05852990 RECRUITING
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Instituto Nacional de Cancerologia de Mexico n=28
NCT06928389 RECRUITING
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Akeso n=536
NCT05445791 RECRUITING
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Instituto Nacional de Cancerologia de Mexico n=312
NCT06545747 RECRUITING
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
Sun Yat-sen University n=490
NCT05047250 ACTIVE NOT RECRUITING
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche n=60
NCT05048797 ACTIVE NOT RECRUITING
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
AstraZeneca n=454
NCT06840704 RECRUITING
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Hunan Cancer Hospital n=121
NCT06472245 RECRUITING
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics n=363
NCT06430866 ACTIVE NOT RECRUITING
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Amgen n=163
NCT06698042 ACTIVE NOT RECRUITING
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Merck Sharp & Dohme LLC n=67
NCT02511106 ACTIVE NOT RECRUITING
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
AstraZeneca n=682
NCT04129502 ACTIVE NOT RECRUITING
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Takeda n=354
NCT06627647 RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca n=878
NCT07149649 NOT YET RECRUITING
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute n=230
NCT05555732 ACTIVE NOT RECRUITING
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo n=1,170
NCT06123754 RECRUITING
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
3D Medicines (Sichuan) Co., Ltd. n=390
NCT04656652 ACTIVE NOT RECRUITING
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo n=605
NCT06396065 ACTIVE NOT RECRUITING
Phase III Study of AK112 for NSCLC Patients
Summit Therapeutics n=420
NCT07477808 NOT YET RECRUITING
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital n=116
NCT06671379 ACTIVE NOT RECRUITING
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=498
NCT04379635 ACTIVE NOT RECRUITING
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeiGene n=453
NCT06012435 ACTIVE NOT RECRUITING
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen, a wholly owned subsidiary of Pfizer n=762
NCT06726265 ACTIVE NOT RECRUITING
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Immutep S.A.S. n=756
NCT04613596 RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc. n=626
NCT05984277 ACTIVE NOT RECRUITING
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
AstraZeneca n=1,200
NCT06284317 RECRUITING
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ETOP IBCSG Partners Foundation n=290
NCT06357533 RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca n=675
NCT03164616 ACTIVE NOT RECRUITING
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
AstraZeneca n=1,186
NCT06881784 RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Revolution Medicines, Inc. n=590
NCT06687369 RECRUITING
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
mAbxience Research S.L. n=726
NCT03003962 ACTIVE NOT RECRUITING
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca n=669
NCT07155187 RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie n=430
NCT07464327 NOT YET RECRUITING
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Hansoh BioMedical R&D Company n=450
NCT07459751 RECRUITING
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech n=706
NCT03178552 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=1,000
NCT07442565 NOT YET RECRUITING
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
CSPC Megalith Biopharmaceutical Co.,Ltd. n=506
NCT04819100 ACTIVE NOT RECRUITING
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company n=152
NCT05184712 ACTIVE NOT RECRUITING
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso n=322
NCT07174908 RECRUITING
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
InxMed (Shanghai) Co., Ltd. n=400
NCT06417814 RECRUITING
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca n=744
NCT04603807 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Hoffmann-La Roche n=220
NCT03774732 ACTIVE NOT RECRUITING
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
UNICANCER n=327
NCT06767514 RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Summit Therapeutics n=780
NCT06236438 RECRUITING
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie n=840
NCT07416994 RECRUITING
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. n=440
NCT05668988 ACTIVE NOT RECRUITING
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Dizal Pharmaceuticals n=324
NCT06956001 RECRUITING
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc. n=300
NCT06970639 RECRUITING
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc. n=380
NCT02152631 ACTIVE NOT RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Eli Lilly and Company n=453
NCT06711900 RECRUITING
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=432
NCT07383116 NOT YET RECRUITING
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd. n=500
NCT07131319 RECRUITING
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Second Affiliated Hospital of Nanchang University n=30
NCT06984588 ACTIVE NOT RECRUITING
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
TJ Biopharma Co., Ltd. n=450
NCT05502237 ACTIVE NOT RECRUITING
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Gilead Sciences n=1,021
NCT06564844 ACTIVE NOT RECRUITING
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
AstraZeneca n=25
NCT05221840 ACTIVE NOT RECRUITING
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
AstraZeneca n=1,051
NCT07365319 RECRUITING
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Eikon Therapeutics n=750
NCT07361484 NOT YET RECRUITING
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
BeyondSpring Pharmaceuticals Inc. n=442
NCT07362459 RECRUITING
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd. n=246
NCT05785767 ACTIVE NOT RECRUITING
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals n=850
NCT05800015 ACTIVE NOT RECRUITING
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals n=950
NCT07360132 NOT YET RECRUITING
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd. n=480
NCT06430437 RECRUITING
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Jiangsu HengRui Medicine Co., Ltd. n=300
NCT02411448 ACTIVE NOT RECRUITING
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Eli Lilly and Company n=545
NCT06899126 RECRUITING
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Daiichi Sankyo n=686
NCT07318883 NOT YET RECRUITING
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech n=720
NCT05609968 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Merck Sharp & Dohme LLC n=614
NCT02201992 ACTIVE NOT RECRUITING
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
ECOG-ACRIN Cancer Research Group n=166
NCT06216301 RECRUITING
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH n=734
NCT06908993 RECRUITING
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique n=133
NCT07182682 RECRUITING
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
Dizal (Jiangsu) Pharmaceutical Co., Ltd. n=360
NCT03851445 RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
SWOG Cancer Research Network n=10,000
NCT07251582 RECRUITING
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital n=156
NCT03052608 ACTIVE NOT RECRUITING
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer n=296
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT07242274 NOT YET RECRUITING
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
Jemincare n=472
NCT06140836 ACTIVE NOT RECRUITING
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Bristol-Myers Squibb n=190
NCT01933932 ACTIVE NOT RECRUITING
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
AstraZeneca n=510
NCT07170995 RECRUITING
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=460
NCT04980716 RECRUITING
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
Sun Yat-sen University n=524
NCT03977194 ACTIVE NOT RECRUITING
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
Intergroupe Francophone de Cancerologie Thoracique n=510
NCT06927986 RECRUITING
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
CSPC Megalith Biopharmaceutical Co.,Ltd. n=380
NCT06348199 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Samsung Bioepis Co., Ltd. n=555
NCT07178795 RECRUITING
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Sichuan Baili Pharmaceutical Co., Ltd. n=440
NCT06212752 ACTIVE NOT RECRUITING
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
Merck Sharp & Dohme LLC n=39
NCT03519971 ACTIVE NOT RECRUITING
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca n=328
NCT04194944 ACTIVE NOT RECRUITING
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Eli Lilly and Company n=261
NCT04025879 ACTIVE NOT RECRUITING
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb n=461
NCT02767804 ACTIVE NOT RECRUITING
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Xcovery Holdings, Inc. n=290
NCT04035486 ACTIVE NOT RECRUITING
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
AstraZeneca n=587
NCT07197853 NOT YET RECRUITING
Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial
Xin Ye n=180
NCT05020769 ACTIVE NOT RECRUITING
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
Sichuan Baili Pharmaceutical Co., Ltd. n=14
NCT07154368 NOT YET RECRUITING
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.
Guangzhou JOYO Pharma Co., Ltd n=207
NCT06840782 RECRUITING
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
Gustave Roussy, Cancer Campus, Grand Paris n=124
NCT05722015 ACTIVE NOT RECRUITING
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
Merck Sharp & Dohme LLC n=377
NCT05278052 RECRUITING
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
Tata Memorial Hospital n=190
NCT05236946 RECRUITING
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Tata Memorial Hospital n=190
NCT07162883 NOT YET RECRUITING
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd. n=122
NCT07150663 RECRUITING
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. n=134
NCT05009836 ACTIVE NOT RECRUITING
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Hutchison Medipharma Limited n=412
NCT06505837 ACTIVE NOT RECRUITING
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）
Shanghai Junshi Bioscience Co., Ltd. n=395
NCT07135882 NOT YET RECRUITING
Primary Radiotherapy In MEtastatic Lung Cancer
Trans Tasman Radiation Oncology Group n=420
NCT04380636 ACTIVE NOT RECRUITING
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Merck Sharp & Dohme LLC n=870
NCT02273375 ACTIVE NOT RECRUITING
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Canadian Cancer Trials Group n=1,415
NCT07109531 NOT YET RECRUITING
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Jiangsu Aosaikang Pharmaceutical Co., Ltd. n=286
NCT05298423 ACTIVE NOT RECRUITING
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Merck Sharp & Dohme LLC n=611
NCT06417008 RECRUITING
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company n=1,080
NCT03789604 ACTIVE NOT RECRUITING
A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer
CStone Pharmaceuticals n=479
NCT06734702 RECRUITING
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Sun Yat-sen University n=497
NCT07052669 RECRUITING
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
Sun Yat-sen University n=311
NCT07076693 ACTIVE NOT RECRUITING
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）
Shanghai Chest Hospital n=97
NCT07050043 RECRUITING
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
Dr Arvindran A/L Alaga n=123
NCT05989542 RECRUITING
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Beijing Pearl Biotechnology Limited Liability Company n=136
NCT05116462 ACTIVE NOT RECRUITING
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. n=506
NCT06980272 RECRUITING
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. n=420
NCT07034326 RECRUITING
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Kong Fanming n=405
NCT05607550 ACTIVE NOT RECRUITING
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma, Inc. n=398
NCT07016126 RECRUITING
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital n=70
NCT03800134 ACTIVE NOT RECRUITING
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
AstraZeneca n=825
NCT06754644 RECRUITING
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Qilu Pharmaceutical Co., Ltd. n=808
NCT07010419 RECRUITING
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
Allist Pharmaceuticals, Inc. n=338
NCT03390686 ACTIVE NOT RECRUITING
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Prestige Biopharma Limited n=650
NCT04351555 ACTIVE NOT RECRUITING
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
AstraZeneca n=358
NCT06082635 ACTIVE NOT RECRUITING
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Shenzhen TargetRx Co., Ltd. n=321
NCT06961188 NOT YET RECRUITING
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Changchun GeneScience Pharmaceutical Co., Ltd. n=174
NCT06955325 NOT YET RECRUITING
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
The First Affiliated Hospital of Guangzhou Medical University n=270
NCT05840016 ACTIVE NOT RECRUITING
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Akeso n=532
NCT06939595 RECRUITING
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
Celltrion n=606
NCT03787992 ACTIVE NOT RECRUITING
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Allist Pharmaceuticals, Inc. n=358
NCT06829459 RECRUITING
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Shanghai JMT-Bio Inc. n=350
NCT04853342 RECRUITING
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Allist Pharmaceuticals, Inc. n=318
NCT06416410 RECRUITING
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Allist Pharmaceuticals, Inc. n=392
NCT06908772 NOT YET RECRUITING
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Shanghai JMT-Bio Inc. n=390
NCT05255302 RECRUITING
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
Intergroupe Francophone de Cancerologie Thoracique n=1,360
NCT06617416 RECRUITING
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Akeso n=560
NCT06872541 ACTIVE NOT RECRUITING
Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas
University of Sao Paulo n=100
NCT06858410 NOT YET RECRUITING
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
Guangdong Association of Clinical Trials n=36
NCT06847334 NOT YET RECRUITING
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Shanghai Henlius Biotech n=772
NCT06828757 NOT YET RECRUITING
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital n=94
NCT05338970 ACTIVE NOT RECRUITING
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Daiichi Sankyo n=586
NCT04597671 ACTIVE NOT RECRUITING
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
Association NVALT Studies n=170
NCT04685135 ACTIVE NOT RECRUITING
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Mirati Therapeutics Inc. n=453
NCT06759857 ENROLLING BY INVITATION
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. n=350
NCT05922345 RECRUITING
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=518
NCT01993810 ACTIVE NOT RECRUITING
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Radiation Therapy Oncology Group n=330
NCT06704620 NOT YET RECRUITING
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital n=430
NCT06735391 RECRUITING
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Shanghai JMT-Bio Inc. n=516
NCT04956692 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Merck Sharp & Dohme LLC n=531
NCT03425643 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Merck Sharp & Dohme LLC n=797
NCT06218069 NOT YET RECRUITING
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
Radboud University Medical Center n=20
NCT04923906 ACTIVE NOT RECRUITING
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=624
NCT04687241 ACTIVE NOT RECRUITING
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=192
NCT06674343 RECRUITING
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Peking Union Medical College Hospital n=144
NCT05487391 RECRUITING
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Qilu Pharmaceutical Co., Ltd. n=632
NCT06523673 RECRUITING
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University n=104
NCT06569420 ACTIVE NOT RECRUITING
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. n=275
NCT05341583 RECRUITING
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. n=202
NCT05654454 RECRUITING
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Mabscale, LLC n=620
NCT03866499 ACTIVE NOT RECRUITING
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
Beta Pharma Shanghai n=369
NCT05668650 RECRUITING
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
Laboratorio Elea Phoenix S.A. n=174
NCT04158440 ACTIVE NOT RECRUITING
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
Shanghai Junshi Bioscience Co., Ltd. n=501
NCT06485557 NOT YET RECRUITING
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
Tang-Du Hospital n=90
NCT06486142 RECRUITING
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Region Skane n=200
NCT04143607 ACTIVE NOT RECRUITING
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. n=337
NCT04322617 RECRUITING
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Hunan Province Tumor Hospital n=1,200
NCT06416852 NOT YET RECRUITING
Clinical Study of 18F-Alfatide Injection PET/CT
Yantai LNC Biotechnology Singapore PTE. LTD. n=428
NCT06300177 RECRUITING
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=522
NCT06380348 NOT YET RECRUITING
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Shanghai JMT-Bio Inc. n=398
NCT06335355 NOT YET RECRUITING
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd n=401
NCT06319313 NOT YET RECRUITING
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. n=534
NCT06254599 NOT YET RECRUITING
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Shouyao Holdings (Beijing) Co. LTD n=255
NCT05382728 RECRUITING
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
TYK Medicines, Inc n=680
NCT06080776 RECRUITING
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Nanjing Sanhome Pharmaceutical, Co., Ltd. n=242
NCT06041776 RECRUITING
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Betta Pharmaceuticals Co., Ltd. n=570
NCT06043973 RECRUITING
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital n=98
NCT06031558 ACTIVE NOT RECRUITING
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co. LTD n=120
NCT05990127 NOT YET RECRUITING
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Akeso n=642
NCT05800223 RECRUITING
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China n=300
NCT05767892 NOT YET RECRUITING
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Suzhou Puhe Pharmaceutical Technology Co., LTD n=350
NCT05429463 RECRUITING
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Second Affiliated Hospital, School of Medicine, Zhejiang University n=250
NCT04951635 RECRUITING
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=150
NCT04762459 ENROLLING BY INVITATION
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
Chinese Academy of Medical Sciences n=606
NCT04772287 NOT YET RECRUITING
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
Shanghai Pulmonary Hospital, Shanghai, China n=341
NCT04465968 NOT YET RECRUITING
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
National Cancer Center Hospital East n=84
NCT07608159 NOT YET RECRUITING
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
Shanghai Pulmonary Hospital, Shanghai, China n=201
NCT07601048 NOT YET RECRUITING
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Shandong Suncadia Medicine Co., Ltd. n=450
NCT07617389 NOT YET RECRUITING
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
Wen-zhao ZHONG n=358
NCT07642024 NOT YET RECRUITING
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
Sichuan Baili Pharmaceutical Co., Ltd. n=90
NCT07640789 NOT YET RECRUITING
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
Sichuan Baili Pharmaceutical Co., Ltd. n=418
NCT07633873 NOT YET RECRUITING
SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）
CSPC Megalith Biopharmaceutical Co.,Ltd. n=500
NCT04536675 ACTIVE NOT RECRUITING
Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery
Samsung Medical Center n=204
NCT07672223 NOT YET RECRUITING
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
CSPC Megalith Biopharmaceutical Co.,Ltd. n=570
NCT07668752 NOT YET RECRUITING
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Genfleet Therapeutics (Shanghai) Inc. n=300
NCT07662811 NOT YET RECRUITING
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
Shanghai Chest Hospital n=396
NCT07660094 RECRUITING
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Candel Therapeutics, Inc. n=500
NCT04746924 TERMINATED
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeiGene n=669
NCT07524257 WITHDRAWN
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
ImmunityBio, Inc.
NCT04702009 COMPLETED
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China n=33
NCT03409614 COMPLETED
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals n=789
NCT05378763 SUSPENDED
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Spectrum Pharmaceuticals, Inc n=268
NCT02296125 COMPLETED
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca n=674
NCT01630733 COMPLETED
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Achieve Life Sciences n=664
NCT03520686 TERMINATED
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc. n=102
NCT06159790 COMPLETED
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sandoz n=218
NCT04205812 COMPLETED
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
Incyte Corporation n=583
NCT02838420 COMPLETED
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=187
NCT02973789 COMPLETED
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure GmbH n=291
NCT02504372 COMPLETED
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Merck Sharp & Dohme LLC n=1,177
NCT02759614 COMPLETED
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
Guangdong Association of Clinical Trials n=311
NCT04222972 TERMINATED
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=223
NCT03631199 TERMINATED
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
Novartis Pharmaceuticals n=673
NCT03829332 COMPLETED
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
Merck Sharp & Dohme LLC n=623
NCT02438722 COMPLETED
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
SWOG Cancer Research Network n=174
NCT03829319 COMPLETED
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
Merck Sharp & Dohme LLC n=761
NCT05226598 COMPLETED
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Merck Sharp & Dohme LLC n=739
NCT04619797 COMPLETED
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche n=542
NCT06267001 TERMINATED
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Hoffmann-La Roche n=56
NCT04294810 COMPLETED
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Hoffmann-La Roche n=620
NCT02998528 COMPLETED
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb n=505
NCT04471428 COMPLETED
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Hoffmann-La Roche n=366
NCT04447118 COMPLETED
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd. n=151
NCT03215706 COMPLETED
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
Bristol-Myers Squibb n=719
NCT03924869 TERMINATED
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
Merck Sharp & Dohme LLC n=448
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03735121 COMPLETED
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche n=438
NCT06280196 TERMINATED
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Bio-Thera Solutions n=162
NCT03469960 COMPLETED
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
Intergroupe Francophone de Cancerologie Thoracique n=265
NCT02831959 COMPLETED
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
NovoCure GmbH n=298
NCT02477826 COMPLETED
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb n=2,747
NCT03906071 COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics Inc. n=577
NCT03596866 COMPLETED
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
Takeda n=248
NCT03653546 COMPLETED
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. n=492
NCT04716933 COMPLETED
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
Merck Sharp & Dohme LLC n=201
NCT04513925 COMPLETED
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=829
NCT01951482 COMPLETED
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
Sun Yat-sen University n=160
NCT03976375 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Merck Sharp & Dohme LLC n=422
NCT04206072 COMPLETED
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Betta Pharmaceuticals Co., Ltd. n=362
NCT04154956 TERMINATED
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Sanofi n=389
NCT02075840 COMPLETED
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Hoffmann-La Roche n=303
NCT04026412 COMPLETED
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Bristol-Myers Squibb n=925
NCT04921358 TERMINATED
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene n=377
NCT06643117 TERMINATED
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
Formycon AG n=25
NCT00981058 COMPLETED
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Eli Lilly and Company n=1,093
NCT05015608 COMPLETED
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Hutchison Medipharma Limited n=216
NCT04427072 TERMINATED
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Novartis Pharmaceuticals n=22
NCT01853826 COMPLETED
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Boehringer Ingelheim n=481
NCT03631706 COMPLETED
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
EMD Serono Research & Development Institute, Inc. n=304
NCT04676412 COMPLETED
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
Merck Sharp & Dohme LLC n=107
NCT04786964 TERMINATED
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Checkpoint Therapeutics, Inc. n=25
NCT04316013 TERMINATED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Peter MacCallum Cancer Centre, Australia n=254
NCT04923945 COMPLETED
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
Hutchison Medipharma Limited n=203
NCT05549037 COMPLETED
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Hunan Province Tumor Hospital n=210
NCT02231164 TERMINATED
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim n=12
NCT03358875 COMPLETED
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
BeiGene n=805
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT01828112 COMPLETED
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis Pharmaceuticals n=231
NCT03663205 COMPLETED
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
BeiGene n=334
NCT02887521 TERMINATED
Pulmonary Rehabilitation Before Lung Cancer Resection
Alliance for Clinical Trials in Oncology n=9
NCT02576574 COMPLETED
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono Research & Development Institute, Inc. n=1,214
NCT01828099 COMPLETED
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis Pharmaceuticals n=376
NCT02754882 COMPLETED
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Samsung Bioepis Co., Ltd. n=763
NCT02588261 TERMINATED
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Astellas Pharma Global Development, Inc. n=530
NCT04248829 COMPLETED
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation n=393
NCT03515837 COMPLETED
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Merck Sharp & Dohme LLC n=492
NCT02613507 COMPLETED
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
Bristol-Myers Squibb n=504
NCT05807893 COMPLETED
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
Sun Yat-sen University n=40
NCT04866017 TERMINATED
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene n=63
NCT03594747 COMPLETED
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
BeiGene n=360
NCT03191786 COMPLETED
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
Hoffmann-La Roche n=453
NCT03447769 TERMINATED
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
Novartis Pharmaceuticals n=1,382
NCT02775435 COMPLETED
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
Merck Sharp & Dohme LLC n=559
NCT04325698 TERMINATED
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Pfizer n=8
NCT03875092 COMPLETED
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
Merck Sharp & Dohme LLC n=125
NCT02864394 COMPLETED
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
Merck Sharp & Dohme LLC n=425
NCT02454933 COMPLETED
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
AstraZeneca n=29
NCT04385368 COMPLETED
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
AstraZeneca n=89
NCT04194203 COMPLETED
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
Hoffmann-La Roche n=305
NCT03195491 COMPLETED
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
Bristol-Myers Squibb n=400
NCT03743051 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA n=318
NCT06093503 WITHDRAWN
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
AbbVie
NCT03743064 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA n=318
NCT02974426 TERMINATED
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital n=132
NCT03117049 COMPLETED
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
Ono Pharmaceutical Co., Ltd. n=550
NCT05493501 TERMINATED
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc. n=8
NCT04816214 TERMINATED
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
Novartis Pharmaceuticals n=6
NCT02654587 TERMINATED
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
OSE Immunotherapeutics n=219
NCT00617656 TERMINATED
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
Spanish Lung Cancer Group n=382
NCT01459497 COMPLETED
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center n=103
NCT01763645 COMPLETED
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer
Biocad n=353
NCT03802240 COMPLETED
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Innovent Biologics (Suzhou) Co. Ltd. n=492
NCT02657434 COMPLETED
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Hoffmann-La Roche n=578
NCT02826161 TERMINATED
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
Sumitomo Pharma America, Inc. n=4
NCT01774721 COMPLETED
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer n=452
NCT02220894 COMPLETED
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Merck Sharp & Dohme LLC n=1,274
NCT02125461 COMPLETED
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
AstraZeneca n=713
NCT03302234 COMPLETED
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
Merck Sharp & Dohme LLC n=568
NCT03850444 COMPLETED
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
Merck Sharp & Dohme LLC n=262
NCT05106335 TERMINATED
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Jiangsu HengRui Medicine Co., Ltd. n=1
NCT05791097 WITHDRAWN
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
Novartis Pharmaceuticals
NCT04466917 WITHDRAWN
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Amgen
NCT01454934 COMPLETED
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Eisai Inc. n=540
NCT03728556 COMPLETED
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
CStone Pharmaceuticals n=381
NCT03306992 COMPLETED
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study
University of Utah n=182
NCT05001724 TERMINATED
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Jiangsu Alphamab Biopharmaceuticals Co., Ltd n=16
NCT02409342 COMPLETED
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Hoffmann-La Roche n=572
NCT01850303 COMPLETED
Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique n=632
NCT01763671 COMPLETED
Paclitaxel-bevacizumab in Advanced Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique n=166
NCT02041533 COMPLETED
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Bristol-Myers Squibb n=541
NCT03351361 COMPLETED
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
Rennes University Hospital n=217
NCT03150875 COMPLETED
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Innovent Biologics (Suzhou) Co. Ltd. n=290
NCT03629925 COMPLETED
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd. n=357
NCT01673867 COMPLETED
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
Bristol-Myers Squibb n=582
NCT03856411 COMPLETED
A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd. n=465
NCT03196986 COMPLETED
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
Beijing Mabworks Biotech Co., Ltd. n=517
NCT03682224 COMPLETED
Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
Southern Illinois University n=57
NCT02813785 COMPLETED
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
Hoffmann-La Roche n=565
NCT01642004 COMPLETED
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
Bristol-Myers Squibb n=272
NCT00858364 TERMINATED
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen n=2,549
NCT03515629 TERMINATED
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals n=5
NCT02066636 COMPLETED
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
Bristol-Myers Squibb n=1,428
NCT01968941 COMPLETED
Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients
Ontario Clinical Oncology Group (OCOG) n=324
NCT02504489 COMPLETED
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
BeyondSpring Pharmaceuticals Inc. n=559
NCT03922997 COMPLETED
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche n=101
NCT01652469 COMPLETED
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
ETOP IBCSG Partners Foundation n=81
NCT04342377 COMPLETED
The Canada Lymph Node Score Project: A Crossover Trial
St. Joseph's Healthcare Hamilton n=80
NCT00966914 COMPLETED
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
BioNumerik Pharmaceuticals, Inc. n=540
NCT02142738 COMPLETED
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Merck Sharp & Dohme LLC n=305
NCT01487174 TERMINATED
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC n=8
NCT02367794 COMPLETED
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Hoffmann-La Roche n=1,021
NCT04633564 COMPLETED
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Mylan Pharmaceuticals Inc n=671
NCT02810457 COMPLETED
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
Centus Biotherapeutics Limited n=731
NCT00982111 COMPLETED
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
Eli Lilly and Company n=633
NCT05169801 COMPLETED
To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC
Jiangsu HengRui Medicine Co., Ltd. n=520
NCT00948675 COMPLETED
Study of Participants With Advanced Non-Small Cell Lung Cancer
Eli Lilly and Company n=361
NCT01905657 COMPLETED
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Merck Sharp & Dohme LLC n=1,034
NCT02366143 COMPLETED
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=1,202
NCT03329911 COMPLETED
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
Bio-Thera Solutions n=651
NCT02737501 COMPLETED
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Ariad Pharmaceuticals n=275
NCT02768558 TERMINATED
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
RTOG Foundation, Inc. n=20
NCT03296163 COMPLETED
A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
mAbxience Research S.L. n=627
NCT02195232 COMPLETED
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Jeffrey Zwicker, MD n=64
NCT02264990 COMPLETED
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
AbbVie n=595
NCT02893332 TERMINATED
Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)
Sichuan Provincial People's Hospital n=200
NCT00738387 TERMINATED
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
Novartis Pharmaceuticals n=900
NCT00662597 TERMINATED
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Novartis Pharmaceuticals n=1,285
NCT02954172 COMPLETED
Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd. n=450
NCT01639001 COMPLETED
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
Pfizer n=207
NCT02106546 COMPLETED
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
AbbVie n=970
NCT01355497 COMPLETED
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
GTx n=330
NCT00880971 COMPLETED
Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer
Chinese Academy of Medical Sciences n=394
NCT01544179 COMPLETED
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
AstraZeneca n=265
NCT02027428 COMPLETED
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Celgene n=427
NCT02395172 COMPLETED
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
EMD Serono Research & Development Institute, Inc. n=792
NCT03745222 TERMINATED
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
Celgene n=1
NCT02004184 TERMINATED
Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy
Norwegian University of Science and Technology n=230
NCT04203511 WITHDRAWN
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Incyte Corporation
NCT03134872 COMPLETED
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd. n=419
NCT01774578 TERMINATED
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
NewLink Genetics Corporation n=135
NCT03331588 COMPLETED
Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China n=200
NCT02272413 COMPLETED
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Boehringer Ingelheim n=671
NCT02008227 COMPLETED
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
Hoffmann-La Roche n=1,225
NCT01667562 COMPLETED
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche n=375
NCT01631357 COMPLETED
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
Tianjin Medical University Cancer Institute and Hospital n=96
NCT02604342 COMPLETED
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Hoffmann-La Roche n=119
NCT01168973 COMPLETED
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
Eli Lilly and Company n=1,253
NCT00775307 COMPLETED
Adjuvant Pazopanib in Stage I NSCLC
Intergroupe Francophone de Cancerologie Thoracique n=142
NCT02187367 TERMINATED
Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients
Bioven Europe n=106
NCT02322281 TERMINATED
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc. n=149
NCT01953913 COMPLETED
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Boehringer Ingelheim n=542
NCT01719536 COMPLETED
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
Betta Pharmaceuticals Co., Ltd. n=296
NCT00693992 COMPLETED
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
National Cancer Institute (NCI) n=210
NCT02186301 TERMINATED
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Clovis Oncology, Inc. n=100
NCT01523587 COMPLETED
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Boehringer Ingelheim n=795
NCT02409355 TERMINATED
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Hoffmann-La Roche n=8
NCT02691299 COMPLETED
A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchison Medipharma Limited n=527
NCT02364999 COMPLETED
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
Pfizer n=719
NCT03058094 WITHDRAWN
A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
NCT02162537 TERMINATED
Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
Centre Hospitalier Intercommunal Creteil n=95
NCT01121393 COMPLETED
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim n=364
NCT00789373 COMPLETED
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
Eli Lilly and Company n=939
NCT00805194 COMPLETED
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
Boehringer Ingelheim n=1,314
NCT03169335 COMPLETED
Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. n=535
NCT01058759 TERMINATED
Taxotere-Enoxaparin-(ENOXA)-Study
Hannover Medical School n=14
NCT03417037 WITHDRAWN
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Bristol-Myers Squibb
NCT02284139 COMPLETED
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
Dong-A University Hospital n=90
NCT03048136 WITHDRAWN
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
Bristol-Myers Squibb
NCT00949650 COMPLETED
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim n=345
NCT03448146 COMPLETED
A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction
PTS International Inc. n=90
NCT01364012 COMPLETED
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
Hoffmann-La Roche n=276
NCT02326285 TERMINATED
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB
AIO-Studien-gGmbH n=1
NCT02134015 TERMINATED
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Daiichi Sankyo n=145
NCT01631136 COMPLETED
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique n=932
NCT01387269 COMPLETED
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Helsinn Therapeutics (U.S.), Inc n=484
NCT01387282 COMPLETED
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Helsinn Therapeutics (U.S.), Inc n=495
NCT01966003 COMPLETED
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Amgen n=642
NCT01351415 COMPLETED
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=485
NCT02388919 COMPLETED
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=439
NCT01395914 COMPLETED
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Helsinn Therapeutics (U.S.), Inc n=513
NCT02049151 TERMINATED
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
EMD Serono n=35
NCT02178397 TERMINATED
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
Centre Francois Baclesse n=6
NCT01360554 COMPLETED
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Pfizer n=878
NCT01999673 COMPLETED
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Peregrine Pharmaceuticals n=582
NCT03117335 COMPLETED
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. n=560
NCT01085136 COMPLETED
LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Boehringer Ingelheim n=1,154
NCT02044380 COMPLETED
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
Boehringer Ingelheim n=14
NCT02031744 COMPLETED
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche n=530
NCT01319669 TERMINATED
Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy
Chinese Society of Lung Cancer n=11
NCT00775385 COMPLETED
TAilored Post-Surgical Therapy in Early Stage NSCLC
Intergroupe Francophone de Cancerologie Thoracique n=152
NCT01724801 COMPLETED
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
Guangdong Association of Clinical Trials n=176
NCT00806819 COMPLETED
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim n=718
NCT01404260 COMPLETED
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials n=219
NCT01351116 COMPLETED
A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy
Ontario Clinical Oncology Group (OCOG) n=134
NCT00932893 COMPLETED
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Pfizer n=347
NCT02795884 WITHDRAWN
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Yonsei University
NCT02988635 COMPLETED
Early Palliative Care on Quality of Life of Advanced Cancer Patients
Azienda Ospedaliero-Universitaria di Parma n=281
NCT01456325 COMPLETED
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Genentech, Inc. n=494
NCT01887886 COMPLETED
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Hoffmann-La Roche n=10
NCT01814553 COMPLETED
ADAM-Afatinib Diarrhea Assessment and Management
Boehringer Ingelheim n=40
NCT01328951 COMPLETED
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
Hoffmann-La Roche n=643
NCT01015443 TERMINATED
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
Merck KGaA, Darmstadt, Germany n=285
NCT00826683 COMPLETED
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)
University Hospital, Limoges n=140
NCT00656136 COMPLETED
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Boehringer Ingelheim n=585
NCT01798485 TERMINATED
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Synta Pharmaceuticals Corp. n=696
NCT00686959 COMPLETED
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Eli Lilly and Company n=598
NCT01441752 COMPLETED
Efficacy Study of Integrated TCM Combined With Chemotherapy in Postoperative NSCLC Patients
xuling n=349
NCT00976456 COMPLETED
Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
PD Dr. med. Wolfgang Schuette n=271
NCT01058902 WITHDRAWN
The Effect Of Aspirin On Survival in Lung Cancer
Liverpool Heart and Chest Hospital NHS Foundation Trust
NCT01355484 COMPLETED
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
GTx n=321
NCT01769066 COMPLETED
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
Fudan University n=117
NCT00961415 COMPLETED
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche n=376
NCT01326767 COMPLETED
Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring
Central European Society for Anticancer Drug Research n=366
NCT00762034 COMPLETED
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company n=939
NCT00883779 COMPLETED
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Hoffmann-La Roche n=451
NCT02629848 TERMINATED
Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
Takeda n=401
NCT01348126 TERMINATED
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Synta Pharmaceuticals Corp. n=385
NCT00738881 TERMINATED
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI) n=23
NCT01183858 COMPLETED
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
Hoffmann-La Roche n=315
NCT01444118 TERMINATED
A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
Bioven Europe
NCT01017874 COMPLETED
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Eli Lilly and Company n=236
NCT02486354 COMPLETED
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Betta Pharmaceuticals Co., Ltd. n=128
NCT00676507 COMPLETED
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
NovaRx Corporation n=532
NCT01379976 TERMINATED
Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer
Mario Negri Institute for Pharmacological Research n=107
NCT01282437 COMPLETED
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
Maastricht Radiation Oncology n=315
NCT01342965 COMPLETED
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
Hoffmann-La Roche n=217
NCT01046383 TERMINATED
Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients
Immunotec Inc. n=16
NCT00718315 COMPLETED
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Hoffmann-La Roche n=201
NCT01761747 TERMINATED
Ponatinib for Squamous Cell Lung and Head and Neck Cancers
Dana-Farber Cancer Institute n=3
NCT00874419 COMPLETED
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
Tongji University n=165
NCT00907504 WITHDRAWN
Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
NCT00820755 COMPLETED
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Merck KGaA, Darmstadt, Germany n=583
NCT01040780 COMPLETED
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
Betta Pharmaceuticals Co., Ltd. n=399
NCT00596830 TERMINATED
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Pfizer n=681
NCT01005680 COMPLETED
A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer
Eli Lilly and Company n=256
NCT01528488 COMPLETED
Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC
Sun Yat-sen University n=118
NCT00864331 COMPLETED
Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy
International Atomic Energy Agency n=251
NCT00673049 TERMINATED
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
Pfizer n=583
NCT00771563 COMPLETED
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
University Hospital, Antwerp n=104
NCT01836575 COMPLETED
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Instituto Nacional de Cancer, Brazil n=228
NCT00931008 COMPLETED
Study to Evaluate SID 530 Compared to Taxotere
SK Chemicals Co., Ltd. n=42
NCT00707304 COMPLETED
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
Agennix n=742
NCT00807066 COMPLETED
Randomized Gefitinib Trial
Fondazione Humanitas per la Ricerca n=1
NCT00522639 TERMINATED
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
Maastricht Radiation Oncology n=120

Full NSCLC Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the NSCLC landscape

How many companies are developing Non-Small Cell Lung Cancer treatments?
41 companies have active or registered Non-Small Cell Lung Cancer programs in TheraRadar's competitive landscape (437 classified trials). The most active are AstraZeneca, Bristol-Myers Squibb, and Sichuan Baili.
What mechanisms of action are being developed for Non-Small Cell Lung Cancer?
57 distinct mechanisms of action appear across the Non-Small Cell Lung Cancer pipeline, including EGFR (next-gen TKI), KRAS G12C, EGFR, EGFR (osimertinib), and PD-1 / VEGF bispecific.
What is the most crowded mechanism in Non-Small Cell Lung Cancer?
EGFR (next-gen TKI) is the most contested mechanism in Non-Small Cell Lung Cancer, with 19 programs mapped to it.
Are there upcoming Non-Small Cell Lung Cancer clinical readouts or FDA decisions?
Near-term Non-Small Cell Lung Cancer catalysts include JMT101 (data readout, Jul '26); JDQ443 (data readout, Aug '26); zongertinib (data readout, Sep '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Non-Small Cell Lung Cancer landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Non-Small Cell Lung Cancer heatmap free to use?
Yes — viewing and searching the Non-Small Cell Lung Cancer heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only